

Amgen Inc.
Condensed Consolidated Statements of Income and
Reconciliation of GAAP Earnings to "Adjusted" Earnings
(In millions, except per share data)
(Unaudited)

	Three Months Ended September 30, 2010			Three Months Ended September 30, 2009		
	GAAP	Adjustments	"Adjusted"	GAAP	Adjustments	"Adjusted"
Revenues:						
Product sales.....	\$ 3,759	\$ -	\$ 3,759	\$ 3,736	\$ -	\$ 3,736
Other revenues.....	57	-	57	76	-	76
Total revenues.....	<u>3,816</u>	<u>-</u>	<u>3,816</u>	<u>3,812</u>	<u>-</u>	<u>3,812</u>
Operating expenses:						
Cost of sales (excludes amortization of certain acquired intangible assets presented below).....	587	(3) (a)	584	545	(3) (a)	542
Research and development.....	719	(12) (a)	689	647	(13) (a)	613
		(18) (b)			(18) (b)	
					(3) (f)	
Selling, general and administrative.....	957	(15) (a)	942	932	(13) (a)	913
					(6) (f)	
Amortization of certain acquired intangible assets.....	74	(74) (c)	-	74	(74) (c)	-
Other.....	-	-	-	9	(8) (e)	-
					(1) (f)	
Total operating expenses.....	<u>2,337</u>	<u>(122)</u>	<u>2,215</u>	<u>2,207</u>	<u>(139)</u>	<u>2,068</u>
Operating income.....	1,479	122	1,601	1,605	139	1,744
Interest expense, net.....	150	(67) (d)	83	139	(63) (d)	76
Interest and other income, net.....	105	-	105	74	-	74
Income before income taxes.....	1,434	189	1,623	1,540	202	1,742
Provision for income taxes.....	198	74 (g)	310	154	80 (h)	224
		38 (i)			(28) (i)	
					18 (k)	
Net income.....	<u>\$ 1,236</u>	<u>\$ 77</u>	<u>\$ 1,313</u>	<u>\$ 1,386</u>	<u>\$ 132</u>	<u>\$ 1,518</u>
Earnings per share:						
Basic	\$ 1.29		\$ 1.37	\$ 1.36		\$ 1.49
Diluted (l)	\$ 1.28		\$ 1.36 (a)	\$ 1.36		\$ 1.49 (a)
Average shares used in calculation of earnings per share:						
Basic	958		958	1,016		1,016
Diluted (l)	962		962 (a)	1,022		1,021 (a)

(a) - (l) See explanatory notes on the following pages.

Amgen Inc.
Condensed Consolidated Statements of Income and
Reconciliation of GAAP Earnings to "Adjusted" Earnings
(In millions, except per share data)
(Unaudited)

	Nine months ended September 30, 2010			Nine months ended September 30, 2009		
	GAAP	Adjustments	"Adjusted"	GAAP	Adjustments	"Adjusted"
Revenues:						
Product sales.....	\$ 10,900	\$ -	\$ 10,900	\$ 10,608	\$ -	\$ 10,608
Other revenues.....	312	-	312	225	-	225
Total revenues.....	<u>11,212</u>	<u>-</u>	<u>11,212</u>	<u>10,833</u>	<u>-</u>	<u>10,833</u>
Cost of sales (excludes amortization of certain acquired intangible assets presented below).....	1,648	(11) (a)	1,637	1,553	(9) (a)	1,543
Research and development.....	2,040	(40) (a)	1,948	1,973	(40) (a)	1,875
Selling, general and administrative.....	2,827	(44) (a)	2,783	2,640	(39) (a)	2,578
Amortization of certain acquired intangible assets.....	221	(221) (c)	-	221	(221) (c)	-
Other.....	(1)	1 (e)	-	63	(28) (e)	-
Total operating expenses.....	<u>6,735</u>	<u>(367)</u>	<u>6,368</u>	<u>6,450</u>	<u>(454)</u>	<u>5,996</u>
Operating income.....	4,477	367	4,844	4,383	454	4,837
Interest expense, net.....	442	(198) (d)	244	436	(186) (d)	250
Interest and other income, net.....	283	-	283	182	-	182
Income before income taxes.....	4,318	565	4,883	4,129	640	4,769
Provision for income taxes.....	713	211 (g)	962	455	235 (h)	820
		38 (i)			87 (i)	
					25 (j)	
					18 (k)	
Net income.....	<u>\$ 3,605</u>	<u>\$ 316</u>	<u>\$ 3,921</u>	<u>\$ 3,674</u>	<u>\$ 275</u>	<u>\$ 3,949</u>
Earnings per share:						
Basic	\$ 3.73		\$ 4.06	\$ 3.60		\$ 3.87
Diluted (l)	\$ 3.71		\$ 4.04 (a)	\$ 3.58		\$ 3.86 (a)
Average shares used in calculation of earnings per share:						
Basic	966		966	1,020		1,020
Diluted (l)	971		971 (a)	1,025		1,024 (a)

(a) - (l) See explanatory notes on the following pages.

Amgen Inc.
Product Sales Detail by Product and Geographic Region
(In millions)
(Unaudited)

	Three months ended September 30,		Nine months ended September 30,	
	2010	2009	2010	2009
Aranesp® - U.S.	\$ 283	\$ 333	\$ 818	\$ 963
Aranesp® - International.....	340	352	1,035	1,041
EPOGEN® - U.S.....	653	663	1,933	1,866
Neulasta® - U.S.	692	657	1,972	1,876
NEUPOGEN® - U.S.	250	240	700	672
Neulasta® - International.....	224	214	668	603
NEUPOGEN® - International.....	88	99	267	290
Enbrel® - U.S.	856	872	2,429	2,430
Enbrel® - Canada	58	52	166	151
Sensipar® - U.S.	115	108	344	320
Sensipar® - International.....	60	57	182	160
Vectibix® - U.S.	30	23	84	72
Vectibix® - International.....	40	35	125	95
Nplate® - U.S.	35	22	95	54
Nplate® - International.....	25	9	69	15
Prolia™ - U.S.	7	-	10	-
Prolia® - International	<u>3</u>	<u>-</u>	<u>3</u>	<u>-</u>
Total product sales	<u>\$ 3,759</u>	<u>\$ 3,736</u>	<u>\$ 10,900</u>	<u>\$ 10,608</u>
U.S.	\$ 2,921	\$ 2,918	\$ 8,385	\$ 8,253
International.....	<u>838</u> (a)	<u>818</u>	<u>2,515</u> (b)	<u>2,355</u>
Total product sales.....	<u>\$ 3,759</u> (a)	<u>\$ 3,736</u>	<u>\$ 10,900</u> (b)	<u>\$ 10,608</u>

(a) The change in international product sales for the three months ended September 30, 2010 was negatively impacted by \$16 million due to unfavorable impact of foreign exchange (including \$7 million for Aranesp®, \$6 million for Neulasta®/NEUPOGEN®, \$3 million for Sensipar®, \$1 million for Vectibix® and \$1 million for Nplate®, partially offset by favorable impact of \$2 million for ENBREL).

(b) The change in international product sales for the nine months ended September 30, 2010 was positively impacted by \$34 million due to favorable impact of in foreign exchange (including \$15 million for Neulasta®/ NEUPOGEN®, \$12 million for Aranesp® and \$8 million for ENBREL, partially offset by unfavorable impact of \$1 million for Sensipar®).

Amgen Inc.
Condensed Consolidated Balance Sheets - GAAP
(In millions)
(Unaudited)

	<u>September 30, 2010</u>	<u>December 31, 2009</u>
Assets		
Current assets:		
Cash, cash equivalents and marketable securities.....	\$ 17,049	\$ 13,442
Trade receivables, net.....	2,443	2,109
Inventories.....	2,044	2,220
Other current assets.....	1,394	1,161
Total current assets.....	<u>22,930</u>	<u>18,932</u>
Property, plant and equipment, net.....	5,643	5,738
Intangible assets, net.....	2,315	2,567
Goodwill.....	11,334	11,335
Other assets.....	1,312	1,057
Total assets.....	<u>\$ 43,534</u>	<u>\$ 39,629</u>
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable and accrued liabilities.....	\$ 3,809	\$ 3,873
Current portion of convertible notes.....	2,451	-
Total current liabilities.....	<u>6,260</u>	<u>3,873</u>
Convertible notes.....	2,263	4,512
Other long-term debt.....	8,578	6,089
Other non-current liabilities.....	2,362	2,488
Stockholders' equity.....	24,071	22,667
Total liabilities and stockholders' equity.....	<u>\$ 43,534</u>	<u>\$ 39,629</u>
Shares outstanding.....	952	995

Amgen Inc.
Reconciliation of GAAP Debt Outstanding to "Adjusted" Debt Outstanding
(In millions)
(Unaudited)

	September 30, 2010			September 30, 2009		
	<u>GAAP</u>	<u>Adjustments for accounting standard</u>	<u>"Adjusted"</u>	<u>GAAP</u>	<u>Adjustments for accounting standard</u>	<u>"Adjusted"</u>
Total debt outstanding.....	\$ 13,292	\$ 368 (a)	\$ 13,660	\$ 11,536	\$ 635 (a)	\$ 12,171

(a) To exclude the impact of adopting an accounting standard on January 1, 2009 that changed the method of accounting for our convertible notes.

Amgen Inc.
Reconciliation of GAAP Stockholders' equity to Stockholders' equity as adjusted for impact of accounting standard
(In millions)
(Unaudited)

	September 30, 2010			September 30, 2009		
	<u>GAAP</u>	<u>Adjustments for accounting standard</u>	<u>"Adjusted"</u>	<u>GAAP</u>	<u>Adjustments for accounting standard</u>	<u>"Adjusted"</u>
Stockholders' equity.....	\$ 24,071	\$ (220) (a)	\$ 23,851	\$ 22,858	\$ (383) (a)	\$ 22,475

(a) To exclude the impact of adopting an accounting standard on January 1, 2009 that changed the method of accounting for our convertible notes.

**Amgen Inc.
Reconciliation of GAAP Earnings Per Share Guidance to "Adjusted"
Earnings Per Share Guidance for the Year Ending December 31, 2010
(Unaudited)**

On October 25, 2010, the Company reaffirmed its "Adjusted" earnings per share guidance towards lower end of \$5.05 to \$5.25, including the estimated impact of the U.S. Health Care Reform Legislation of slightly below \$200 million. The following table shows a reconciliation of GAAP earnings per share (diluted) guidance to "Adjusted" earnings per share (diluted) guidance.

	<u>2010</u>
GAAP earnings per share (diluted) guidance	\$ 4.59 - \$ 4.80
Known adjustments to arrive at "Adjusted" earnings*:	
Amortization of acquired intangible assets, product technology rights..... (a)	0.19
Incremental non-cash interest expense..... (b)	0.17
Stock option expense..... (c)	0.08 - 0.09
Amortization of acquired intangible assets, R&D technology rights..... (d)	0.05
Tax settlement..... (e)	<u>(0.04)</u>
"Adjusted" earnings per share (diluted) guidance	<u>\$ 5.05 - \$ 5.25</u>

* The known adjustments are presented, where applicable, net of their related aggregate tax impact of approximately \$0.28 to \$0.29 per share.

- (a) To exclude the ongoing, non-cash amortization of acquired product technology rights, primarily ENBREL, related to the Immunex acquisition.
- (b) To exclude the incremental non-cash interest expense resulting from a change in accounting in January 2009 related to our convertible debt.
- (c) To exclude stock option expense.
- (d) To exclude the ongoing, non-cash amortization of the R&D technology intangible assets acquired with the Abgenix and Avidia acquisitions.
- (e) To exclude the income tax benefit recognized as a result of resolving certain non-routine transfer pricing issues with tax authorities for prior periods.

**Amgen Inc.
Reconciliation of GAAP Tax Rate Guidance to "Adjusted"
Tax Rate Guidance for the Year Ending December 31, 2010
(Unaudited)**

On October 25, 2010, the Company stated that it now expects its "Adjusted" tax rate guidance to be around 20%. The tax rate effect of known adjustments discussed above is approximately 3%, resulting in GAAP tax rate guidance of approximately 17%.